首页> 外文期刊>Japanese Journal of Pharmacology >Improvement of Pentobarbital-Induced Heart Failure by MCI-154, a Novel and Potent Cardiotonic Agent, in the Dog Heart-Lung Preparation
【24h】

Improvement of Pentobarbital-Induced Heart Failure by MCI-154, a Novel and Potent Cardiotonic Agent, in the Dog Heart-Lung Preparation

机译:MCI-154,一种新颖的强心剂,改善狗戊巴比妥所致的心力衰竭,用于狗心肺制剂

获取原文
获取外文期刊封面目录资料

摘要

References(11) Cited-By(5) The efficacy of MCI-154, a new pyridazinone cardiotonic agent, in improving heart failure was assessed in dog heart-lung preparations in which cardiac function had been severely depressed by pentobarbital. MCI-154 in doses of 10-100 μig improved the cardiac function curve and restored it to the control level at 100 μg. At this dose, MCI-154 neither produced an increase in heart rate beyond the control value nor induced arrhythmias. The effects of MCI-154 were not affected by atenolol, a cardioselective β1-blocker. These results indicate that MCI-154 would be of potential use in the treatment of heart failure.
机译:参考文献(11)引用(5)在犬的心肺制剂中评估了新型哒嗪酮强心药MCI-154在改善心力衰竭中的功效,在这些犬的心肺制剂中,戊巴比妥会严重抑制心脏功能。 MCI-154的剂量为10-100μig,可改善心脏功能曲线,并将其恢复至100μg的对照水平。在此剂量下,MCI-154既不会使心率增加超过控制值,也不会引起心律不齐。 MCI-154的作用不受心脏选择性β1阻断剂阿替洛尔的影响。这些结果表明,MCI-154在心力衰竭的治疗中可能具有潜在用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号